Understanding aldosterone in hypertension among Kaiser Permanente members
Official title: REFOCUS-HTN US-WEST: a Data Infrastructure to Characterize Contemporary Individuals With Hypertension, Their Care, Health Outcomes, and Wellbeing
Run by Kaiser Permanente · NCT07780500 · Data updated 2026-11-12
This is an observational program to see how aldosterone relates to high blood pressure in adults with hypertension, using data from Kaiser Permanente members in Northern California.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Kaiser Permanente Academic / other |
| Locations | 1 site (Oakland, California) |
| Status | Recruiting |
| Started | August 20, 2026 |
| Main results expected | March 2028 |
| Study ends | March 2029 |
| Registry record updated | October 5, 2026 |
| Trial ID | NCT07780500 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 and older with established hypertension within Kaiser Permanente Northern California, with 6+ months of continuous health coverage and meeting recent screening criteria for aldosterone dysregulation.
✕Probably not a fit
Individuals without aldosterone-related hypertension or without eligibility criteria may not see direct benefits from this observational work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
REFOCUS-HTN US-WEST is an observational program combining retrospective data and a prospective sub-study called SCALED to describe aldosterone dysregulation in hypertension. The SCALED sub-study enrolls about 500 adults from the REFOCUS-HTN cohort and collects primary data at baseline to explore the role of aldosterone in resistant and stage 2 hypertension. The project aligns with updated guidelines that emphasize screening for primary aldosteronism and aims to inform individualized and population-level hypertension management. Data are drawn from electronic health records and new clinical assessments to characterize prevalence, clinical features, and potential treatment implications. The lead sponsor is Kaiser Permanente with collaboration from AstraZeneca, focusing on the Northern California region.
Why it matters
Potential benefit: If successful, the study could improve identification of aldosterone-related hypertension and inform more targeted, individualized management strategies.
How similar studies have gone: Previous observational work in this area has provided foundational insights but this program offers prospective data collection to better describe aldosterone dysregulation in a real-world setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: The SCALED Cohort will be identified from the REFOCUS-HTN Cohort which includes men and women ≥ 18 years of age with established hypertension in the KPNC EHR from January 2012 through March 31, 2029. Established hypertension will be defined as one of the following: * ≥1 outpatient, non-emergency department diagnosis of hypertension; * ≥2 consecutive outpatient measures of systolic blood pressure ≥130 mmHg at least 90 days apart; * ≥2 consecutive outpatient measures of diastolic blood pressure ≥80 mmHg at least 90 days apart. Additional Eligibility Criteria for SCALED: * Hypertension diagnosis within the past 18 months prior to screening. * At least 6 months of continuous health plan coverage prior to initial visit. Exclusion Criteria: * Diagnosed cause of secondary hypertension from drug or alcohol induced, or renovascular hypertension; * Bariatric surgery or GLP1 prescription in the last 12 months; * Exposure to an aldosterone synthase inhibitor or a mineralocorticoid receptor antagonist in the last 12 weeks; * Last known estimated glomerular filtration rate \< 45 mL/min/1.73m2 (according to the CKD-EPI equation) at the time of screening; * Kidney transplant; * Currently receiving dialysis; * Current enrollment in any cardiovascular or blood pressure interventional trial.
Where it's running
-
Kaiser Permanente Northern California
Oakland, California, United States Recruiting
Study contacts
- Study coordinator: Ankeet S Bhatt, MD, MBA, ScM
- Email: Ankeet.S.Bhatt@kp.org
- Phone: 415-470-6571
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Monitoring progression of chronic cardiovascular conditions
This project will collect wearable physiologic data from adults with cardiovascular conditions to see how their heart disease changes over time.
-
Using low-dose aspirin after preeclampsia to improve recovery
This study is testing if taking low-dose aspirin for six months after having preeclampsia can help new moms recover better by improving their blood pressure and blood vessel function.
-
IMB-guided health education to boost medication taking and blood pressure control in adults with hypertension
This study tests a health-literacy program based on Information-Motivation-Behavioral Skills to help adults with hypertension who don’t take their medicines regularly to take them more consistently and better control their blood pressure.
-
Renal Nerve Stimulation to Help Blood Pressure in AF and HFpEF
This study tests whether stimulating the kidneys with a catheter can safely lower blood pressure in adults with atrial fibrillation and HFpEF who also have hypertension.
-
Hypertension: Does Education Help Patients Manage Blood Pressure Better?
This study tests whether structured patient education improves blood pressure control and self-management in adults with hypertension who speak Turkish.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.